Collected Dataset / VIP_alloSCT-28_days_post_vaccination

• Canada

• Participants are diagnosed with hematologic malignancy. Patients with Chronic Grade II-IV graft-versus-host-disease may only be included if they are elligible for vaccination.

  Participants are excluded if they have chronic myelogenous leukemia, myeloproliferative neoplasm not on cytoreductive therapy, or any absolute contraindications to the COVID-19 vaccine.

Participants are included if it has been at least 3 months since they have received an allogeneic hematopoietic stem cell transplant from the time of enrollment.

Participants are excluded if they received an autologous stem cell transplantation (autoSCT) or allogeneic hematopoietic stem cell transplantation (alloSCT) treatment for non-hematologic malignancy diseases.

• Specific population

• Clinic patients